{"id":50484,"date":"2022-11-04T01:02:18","date_gmt":"2022-11-04T00:02:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/"},"modified":"2022-11-04T01:02:18","modified_gmt":"2022-11-04T00:02:18","slug":"cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/","title":{"rendered":"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline"},"content":{"rendered":"
\n

\n–Company also strengthens Board of Directors with appointments of Luca Santarelli and Michael Tomsicek–<\/i>\n<\/p>\n

BASEL, Switzerland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the acceptance of two abstracts for the company\u2019s pipeline programs to be presented at the American Society of Hematology meeting in December 2022 in New Orleans.\n<\/p>\n

<\/a><\/p>\n

\nIn addition, the company has strengthened its board of directors with the additions of Luca Santarelli, M.D., and Michael Tomsicek.\n<\/p>\n

\nASH abstracts<\/b>\n<\/p>\n

\nCimeio\u2019s SCIP platform (Shielded Cell & Immunotherapy Pairs) uses gene editing tools to insert novel protein variants into hematopoietic stem cells or other types of cells, allowing the cells to maintain their function while making them resistant to paired immunotherapy depletion. Cimeio\u2019s platform has effectively shielded cells from depletion mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells in preclinical studies. The company is advancing its first programs towards clinical development for genetic and malignant hematologic diseases.\n<\/p>\n

\nThe first abstract to be presented at the upcoming ASH meeting is titled \u201cFunction-preserving single amino acid substitutions shield hematopoietic stem and progenitor cells from CD117 targeted immunotherapy in vivo.\u201d This describes how CD117-shielded HSPCs could enable higher, longer and\/or repetitive antibody dosing, allowing for toxin-free conditioning, post-transplant adjustment of donor chimerism, and targeted treatment of minimal residual disease in CD117+ malignancies.\n<\/p>\n

\nThe second abstract is titled \u201cEngineered Single Amino Acid Substitutions Protect Hematopoietic Stem and Progenitor Cells From CD123 Targeted Immunotherapy.\u201d These findings detail how single amino acid substitutions in CD123 introduced to HSPCs by CRISPR\/Cas9-mediated HDR enable selective shielding from various immunotherapies, while preserving biophysical and functional properties.\n<\/p>\n

\n\u201cWith the presentation of our first preclinical data we have demonstrated that our shielding technology works in vivo, and across two of our leading programs,\u201d said Cimeio CEO Thomas Fuchs. \u201cOur CD117 shield results in no residual binding when paired with our highly potent CD117 antibody. This pair serves as the basis for a powerful combination that could transform HSCT for patients with severe genetic and malignant hematological diseases.\u201d\n<\/p>\n

\nPresentation details<\/b>\n<\/p>\n

\nTitle:<\/b> Function-Preserving Single Amino Acid Substitutions Shield Hematopoietic Stem and Progenitor Cells from CD117 Targeted Immunotherapy In Vivo
\n
Session Name:<\/b> 701. Experimental Transplantation: Basic and Translational: Poster I
\n
Session Date:<\/b> Saturday, December 10, 2022
\n
Presentation Time:<\/b> 5:30 PM – 7:30 PM
\n
Location:<\/b> Ernest N. Morial Convention Center, Hall D\n<\/p>\n

\nTitle:<\/b> Engineered Single Amino Acid Substitutions Protect Hematopoietic Stem and Progenitor Cells from CD123 Targeted Immunotherapy
\n
Session Name:<\/b> 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II
\n
Session Date:<\/b> Sunday, December 11, 2022
\n
Presentation Time:<\/b> 6:00 PM – 8:00 PM
\n
Location:<\/b> Ernest N. Morial Convention Center, Hall D\n<\/p>\n

\nBoard appointments<\/b>\n<\/p>\n

\nDr. Santarelli is the founder and CEO of VectivBio, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions. He has more than 20 years of experience in academic and industrial R&D, having led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization. Previously, Dr. Santarelli served as Chief Executive Officer and co-founder of Therachon AG, which was acquired by Pfizer Inc. in 2019 for $810 million.\n<\/p>\n

\nPrior to Therachon, he spent 12 years at Roche, most recently serving as the Senior Vice President and Head of Neuroscience, Ophthalmology and Rare Diseases, as well as Small Molecule Research at Roche in Switzerland. Dr. Santarelli completed his M.D. and Psychiatry Residency at the University of Turin, Italy, and a postdoctoral fellowship at Columbia University, focusing on the molecular mechanisms of psychiatric disorders and adult brain stem cells.\n<\/p>\n

\nMr. Tomsicek is the former CFO of CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases. Prior to joining CRISPR, Mr. Tomsicek served as CFO of Abiomed and before that was SVP and CFO at Cubist Pharmaceuticals.\n<\/p>\n

\nPrior to Cubist, Mr. Tomsicek spent nearly eight years at General Electric Healthcare, as finance manager in global operations, and then as CFO of its ultrasound business. He holds a bachelor of science degree in engineering and a master of business administration, both from the University of Wisconsin.\n<\/p>\n

\n\u201cWe are very pleased to welcome Luca and Mike to the Cimeio Board. They are both seasoned biotech executives who will be instrumental as we grow the company in this next phase,\u201d said Alex Mayweg, Ph.D., Chairman of Cimeio and Managing Director at founding investor Versant Ventures.\n<\/p>\n

\nAbout Cimeio<\/b>\n<\/p>\n

\nCimeio is an applied gene editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs\u2122 (SCIP), which has the potential to transform hematopoietic stem cell transplant. Cimeio\u2019s technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders. For more information, please visit www.cimeio.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSteve Edelson
\n
sedelson@versantventures.com<\/a>
415-801-8088\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

–Company also strengthens Board of Directors with appointments of Luca Santarelli and Michael Tomsicek– BASEL, Switzerland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the acceptance of two abstracts for the company\u2019s pipeline programs to be presented at the American Society of Hematology meeting in December … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50484","6":"format-standard","7":"category-industry"},"yoast_head":"\nCimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"–Company also strengthens Board of Directors with appointments of Luca Santarelli and Michael Tomsicek– BASEL, Switzerland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the acceptance of two abstracts for the company\u2019s pipeline programs to be presented at the American Society of Hematology meeting in December ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-04T00:02:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221103006404\/en\/1625697\/21\/Cimeio_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline\",\"datePublished\":\"2022-11-04T00:02:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/\"},\"wordCount\":861,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006404\\\/en\\\/1625697\\\/21\\\/Cimeio_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/\",\"name\":\"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006404\\\/en\\\/1625697\\\/21\\\/Cimeio_logo.jpg\",\"datePublished\":\"2022-11-04T00:02:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006404\\\/en\\\/1625697\\\/21\\\/Cimeio_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006404\\\/en\\\/1625697\\\/21\\\/Cimeio_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline - Pharma Trend","og_description":"–Company also strengthens Board of Directors with appointments of Luca Santarelli and Michael Tomsicek– BASEL, Switzerland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the acceptance of two abstracts for the company\u2019s pipeline programs to be presented at the American Society of Hematology meeting in December ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-04T00:02:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221103006404\/en\/1625697\/21\/Cimeio_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline","datePublished":"2022-11-04T00:02:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/"},"wordCount":861,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103006404\/en\/1625697\/21\/Cimeio_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/","url":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/","name":"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103006404\/en\/1625697\/21\/Cimeio_logo.jpg","datePublished":"2022-11-04T00:02:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221103006404\/en\/1625697\/21\/Cimeio_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221103006404\/en\/1625697\/21\/Cimeio_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50484"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50484\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}